Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Candel Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 21 | 21 | 0 |
| Shares | 5.42M | 5.48M | +57.6K (+1.1%) |
| Value | $9.70M | $7.44M | −$2.26M (−23.3%) |
New holders (4)
Institutions that held Candel Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Baystate Wealth Management LLC | 105,854 | $142.9K | 0.01% |
| Citadel Advisors LLC | 47,174 | $64.6K | 0.00% |
| Resources Investment Advisors, LLC. | 25,428 | $34.3K | 0.00% |
| Renaissance Technologies LLC | 21,000 | $28.0K | 0.00% |
Sold out (4)
Institutions that held Candel Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Jane Street Group, LLC | 13,425 | $24.0K |
| Citigroup Inc | 352 | $630 |
| Morgan Stanley | 92 | $165 |
| Bank of America Corp | 22 | $40 |